NCT02563769View on ClinicalTrials.gov

Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

May 25, 2018

Study Completion Date

May 25, 2018

Conditions
Cocaine DependenceCocaine AddictionCocaine AbuseCocaine-Related Disorders
Interventions
DRUG

Clavulanic acid

Clavulanic acid will be administered orally in 250mg capsules

DRUG

Intravenous cocaine

20/40mg Cocaine will be administered by IV

DRUG

Placebo

Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose

Trial Locations (1)

19125

Temple University Hospital - Episcopal Campus, Philadelphia

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

University of Pennsylvania

OTHER

lead

Temple University

OTHER

NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study | Biotech Hunter | Biotech Hunter